Cipla and DNDi launch child-friendly 4-in-1 antiretroviral treatment for young children living with HIV in South Africa

Cipla and DNDi launch child-friendly 4-in-1 antiretroviral treatment for young children living with HIV in South Africa Submission Details

Author: Vergas Mabunda from Tribeca PR.
More Info link:
Images: For a high res version of THIS image please contact Tribeca PR.

Media contacts
CIPLA SOUTH AFRICA MEDIA CONTACT
Fidelia van der Linde
Communications manager
Fidelia.vanderLinde@cipla.com

About DNDi
A not-for-profit research and development organization, DNDi works to deliver new treatments for neglected patients, those living with Chagas disease, sleeping sickness (human African trypanosomiasis), leishmaniasis, filarial infections, mycetoma, paediatric HIV, and hepatitis C. DNDi is also coordinating the ANTICOV clinical trial to find treatments for mild-to-moderate COVID-19 cases in Africa. Since its inception in 2003, DNDi has delivered eleven new treatments to date, including new drug combinations for kala-azar, two fixed-dose antimalarials, and DNDi’s first successfully developed new chemical entity, fexinidazole, approved in 2018 for the treatment of both stages of sleeping sickness. www.dndi.org

About Cipla
Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 47 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Mar’22), 3rd largest in the pharma private market in South Africa (IQVIA MAT Mar’22), and is among the most dispensed generic players in the U.S.
For over eight decades, making a difference to patients has inspired every aspect of Cipla’s work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla’s humanitarian approach to healthcare in pursuit of its purpose of ‘Caring for Life’ and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit www.cipla.com, or click on Twitter, Facebook, LinkedIn.

About Cipla South Africa:
Cipla Medpro South Africa (Pty) Limited (‘Cipla Medpro’) is a wholly owned subsidiary of Cipla Limited, India (‘Cipla’) and third largest pharmaceutical company in the private sector in South Africa. Through Cipla’s ethos of ‘Caring for Life’, Cipla Medpro produces world-class medicines at affordable prices for the public and private sectors, advancing healthcare for all South Africans.
For more information, visit www.cipla.co.za

Have a look at the online visibility from 06/15/2022 to today for Cipla and DNDi launch child-friendly 4-in-1 antiretroviral treatment for young children living with HIV in South Africa:

1. Google Search Results
2. Bing Search Results
3. Yahoo Search Results
4. DuckDuckGo Search Results
5. Twitter Mentions

SUBMIT Your Press Release HERE

Hint: Registering on MyPR and ensuring that you are logged in when submitting your press release will seamlessly place your releases under your Author Name. OR – Log in HERE. See our Guidelines.

We are looking for a certain standard and provide these handy hints to help you:

1. Answer the 5W’s and 1H: Who, What, When, Where, Why and How.
2. Be objective (keep opinions and ‘flowery language’ out of the story).
3. Get your facts right.
4. Don’t plagiarise.
5. Give credit where it is due.
6. Cite references.
7. Provide URL’s so that your readers can discover more.
8. Rather be accurate than first.
9. Start with the most important facts first and follow with supporting information.
10. Don’t copy and paste your press release from word processing software – use notepad or other.
11. See – Google’s Updated Link Schemes Policy and MyPR – for more info.

The press releases that gain the most attention adhere to the above guidelines, are entertaining and are NOT pure sales pitches.

Return to top of page

NOTE: Any press releases that do not follow the above guidelines or have no bearing on South Africa, are thinly disguised adverts with no ‘meat’ are deleted.